NASDAQ$EXAS
Exact Sciences Corp · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Exact Sciences reported strong Q4 2020 results, driven by its screening and precision oncology segments, despite challenges posed by the pandemic.
Exact Sciences Corp. announced Q4 2020 revenue of $466.3 million and full year revenue of $1,491.4 million. The company's performance was driven by its Cologuard and Oncotype tests. The company reported a net loss of $(436.8) million, or $(2.79) per share, and adjusted EBITDA of $87.9 million.
- Total revenue for Q4 2020 was $466.3 million.
- Screening revenue increased to $249.7 million, a 9% increase year-over-year.
- Precision Oncology revenue was $117.6 million.
- COVID-19 testing revenue was $99.1 million.
Headline financials
Revenue & EPS history
Exact Sciences · Revenue · Quarterly
$466M
Revenue by segment
Exact Sciences · $367M total across 2 segments · Q4 2020
- Screening$250M+8.8%68.0%
- Precision Oncology$118M+77.6%32.0%
Forward guidance
The company did not provide specific forward guidance in this earnings report.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2020
+0.8%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+3.4%
Avg return
30 days after
55%
35 / 64 earnings
Positive
+35.0%
Q2 2016
Best reaction
-27.1%
Q3 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | — | — | — | |
| Q4 2025 | +0.0% | +0.0% | +0.7% | |
| Q3 2025 | +3.8% | -1.2% | +51.0% | |
| Q2 2025 | -8.2% | -11.0% | +14.7% | |
| Q1 2025 | +9.1% | +13.0% | +19.3% | |
| Q4 2024 | -1.9% | -0.6% | -9.6% | |
| Q3 2024 | -23.1% | -27.6% | -12.0% | |
| Q2 2024 | +24.3% | +19.7% | +32.4% | |
| Q1 2024 | -11.8% | -9.5% | -30.1% | |
| Q4 2023 | -5.2% | -8.3% | -1.0% | |
| Q3 2023 | +1.4% | +5.9% | +8.8% | |
| Q2 2023 | -12.7% | -12.6% | -14.2% | |
| Q1 2023 | +14.9% | +15.5% | +32.2% | |
| Q4 2022 | +1.9% | -5.4% | +3.0% | |
| Q3 2022 | +13.8% | +23.9% | +40.4% | |
| Q2 2022 | +0.8% | -0.3% | -23.2% | |
| Q1 2022 | -0.2% | -12.1% | -20.4% | |
| Q4 2021 | -6.9% | +5.7% | -9.5% | |
| Q3 2021 | -3.2% | +3.3% | -17.3% | |
| Q2 2021 | -0.0% | -3.2% | -7.2% | |
| Q1 2021 | -11.9% | -16.8% | -14.0% | |
| Q4 2020 | -9.0% | -4.6% | -17.4% | |
| Q3 2020 | +19.7% | +16.2% | +8.7% | |
| Q2 2020 | +0.1% | -1.8% | -22.7% | |
| Q1 2020 | +6.3% | +7.7% | +11.3% | |
| Q4 2019 | -1.1% | +1.4% | -46.8% | |
| Q3 2019 | -9.5% | -3.1% | -12.2% | |
| Q2 2019 | -0.0% | -2.4% | +1.9% | |
| Q1 2019 | -0.9% | +6.7% | +3.5% | |
| Q4 2018 | +10.1% | +10.7% | +6.4% | |
| Q3 2018 | +15.5% | +20.7% | +23.3% | |
| Q2 2018 | -11.7% | -12.9% | +28.1% | |
| Q1 2018 | +14.9% | +10.5% | +14.5% | |
| Q4 2017 | -9.2% | -4.9% | -5.4% | |
| Q3 2017 | +7.5% | +10.8% | +13.0% | |
| Q2 2017 | +0.5% | +0.1% | +4.2% | |
| Q1 2017 | +26.1% | +30.1% | +40.0% | |
| Q4 2016 | +14.0% | +7.6% | +2.9% | |
| Q3 2016 | -22.1% | -20.5% | -19.3% | |
| Q2 2016 | +35.0% | +39.5% | +52.9% | |
| Q1 2016 | -16.9% | — | — | |
| Q4 2015 | -9.5% | — | — | |
| Q3 2015 | +1.0% | — | — | |
| Q2 2015 | -8.9% | — | — | |
| Q1 2015 | +6.2% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | +6.1% | — | — | |
| Q2 2014 | +1.1% | — | — | |
| Q1 2014 | +0.7% | — | — | |
| Q4 2013 | +10.5% | — | — | |
| Q3 2013 | -1.0% | — | — | |
| Q2 2013 | -8.0% | — | — | |
| Q1 2013 | +2.4% | — | — | |
| Q4 2012 | +2.7% | — | — | |
| Q3 2012 | +5.4% | — | — | |
| Q2 2012 | +5.4% | — | — | |
| Q1 2012 | +1.4% | — | — | |
| Q4 2011 | +4.6% | — | — | |
| Q3 2011 | -4.1% | — | — | |
| Q2 2011 | -6.7% | — | — | |
| Q1 2011 | +1.6% | — | — | |
| Q4 2010 | +2.8% | — | — | |
| Q3 2010 | -27.1% | — | — | |
| Q2 2010 | +3.3% | — | — | |
| Q1 2010 | +6.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro